<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Prognostic factors for response and survival in higher-risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> patients treated with <z:chebi fb="0" ids="2038">azacitidine</z:chebi> (AZA) remain largely unknown </plain></SENT>
<SENT sid="1" pm="."><plain>Two hundred eighty-two consecutive high or intermediate-2 risk <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> patients received AZA in a compassionate, patient-named program </plain></SENT>
<SENT sid="2" pm="."><plain>Diagnosis was RA/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> in 4%, <z:e sem="disease" ids="C1318550" disease_type="Neoplastic Process" abbrv="">RAEB-1</z:e> in 20%, <z:e sem="disease" ids="C1318551" disease_type="Neoplastic Process" abbrv="">RAEB-2</z:e> in 54%, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> with 21%-30% marrow blasts) in 22% </plain></SENT>
<SENT sid="3" pm="."><plain>Cytogenetic risk was good in 31%, intermediate in 17%, and poor in 47% </plain></SENT>
<SENT sid="4" pm="."><plain>Patients received AZA for a median of 6 cycles (1-52) </plain></SENT>
<SENT sid="5" pm="."><plain>Previous low-dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> treatment (P = .009), bone marrow blasts &gt; 15% (P = .004), and abnormal karyotype (P = .03) independently predicted lower response rates </plain></SENT>
<SENT sid="6" pm="."><plain>Complex karyotype predicted shorter responses (P = .0003) </plain></SENT>
<SENT sid="7" pm="."><plain>Performance status ≥ 2, intermediate- and poor-risk cytogenetics, presence of circulating blasts, and red blood cell transfusion dependency ≥ 4 units/8 weeks (<z:hpo ids='HP_0000001'>all</z:hpo> P &lt; 10(-4)) independently predicted poorer overall survival (OS) </plain></SENT>
<SENT sid="8" pm="."><plain>A prognostic score based on those factors discriminated 3 risk groups with median OS not reached, 15.0 and 6.1 months, respectively (P &lt; 10(-4)) </plain></SENT>
<SENT sid="9" pm="."><plain>This prognostic score was validated in an independent set of patients receiving AZA in the AZA-001 trial (P = .003) </plain></SENT>
<SENT sid="10" pm="."><plain>Achievement of hematological improvement in patients who did not obtain complete or partial remission was associated with improved OS (P &lt; 10(-4)) </plain></SENT>
<SENT sid="11" pm="."><plain>In conclusion, routine tests can identify subgroups of patients with distinct prognosis with AZA treatment </plain></SENT>
</text></document>